184 related articles for article (PubMed ID: 23885194)
1. Development and evaluation of agents for targeting visceral amyloid.
Wall JS; Solomon A; Kennel SJ
Tijdschr Nucl Geneeskd; 2011 Dec; 33(4):807-814. PubMed ID: 23885194
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.
Wall JS; Williams AD; Foster JS; Richey T; Stuckey A; Macy S; Wooliver C; Campagna SR; Tague ED; Farmer AT; Lands RH; Martin EB; Heidel RE; Kennel SJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10839-E10848. PubMed ID: 30377267
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis.
Wall JS; Martin EB; Richey T; Stuckey AC; Macy S; Wooliver C; Williams A; Foster JS; McWilliams-Koeppen P; Uberbacher E; Cheng X; Kennel SJ
Molecules; 2015 Apr; 20(5):7657-82. PubMed ID: 25923515
[TBL] [Abstract][Full Text] [Related]
4. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody.
Wall JS; Kennel SJ; Paulus M; Gregor J; Richey T; Avenell J; Yap J; Townsend D; Weiss DT; Solomon A
J Nucl Med; 2006 Dec; 47(12):2016-24. PubMed ID: 17138745
[TBL] [Abstract][Full Text] [Related]
5. The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice.
Kennel SJ; Williams A; Stuckey A; Richey T; Wooliver C; Chazin W; Stern DA; Martin EB; Wall JS
Amyloid; 2016; 23(1):8-16. PubMed ID: 26701064
[TBL] [Abstract][Full Text] [Related]
6. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts.
Martin EB; Williams A; Heidel E; Macy S; Kennel SJ; Wall JS
Biochem Biophys Res Commun; 2013 Jun; 436(1):85-9. PubMed ID: 23707811
[TBL] [Abstract][Full Text] [Related]
7. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.
Wall JS; Richey T; Stuckey A; Donnell R; Macy S; Martin EB; Williams A; Higuchi K; Kennel SJ
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E586-94. PubMed ID: 21807994
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion.
Foster JS; Balachandran M; Hancock TJ; Martin EB; Macy S; Wooliver C; Richey T; Stuckey A; Williams AD; Jackson JW; Kennel SJ; Wall JS
Front Immunol; 2023; 14():1275372. PubMed ID: 37854603
[TBL] [Abstract][Full Text] [Related]
9. Micro-imaging of amyloid in mice.
Wall JS; Paulus MJ; Gleason S; Gregor J; Solomon A; Kennel SJ
Methods Enzymol; 2006; 412():161-82. PubMed ID: 17046658
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.
Martin EB; Williams A; Richey T; Stuckey A; Heidel RE; Kennel SJ; Wall JS
Sci Rep; 2016 Mar; 6():22695. PubMed ID: 26936002
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT.
Wall JS; Richey T; Williams A; Stuckey A; Osborne D; Martin E; Kennel SJ
Mol Imaging Biol; 2012 Aug; 14(4):402-7. PubMed ID: 22042488
[TBL] [Abstract][Full Text] [Related]
13. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
14. Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation.
Martin EB; Kennel SJ; Richey T; Wooliver C; Osborne D; Williams A; Stuckey A; Wall JS
Peptides; 2014 Oct; 60():63-70. PubMed ID: 25102446
[TBL] [Abstract][Full Text] [Related]
15. Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body
Ehman EC; El-Sady MS; Kijewski MF; Khor YM; Jacob S; Ruberg FL; Sanchorawala V; Landau H; Yee AJ; Bianchi G; Di Carli MF; Falk RH; Hyun H; Dorbala S
J Nucl Med; 2019 Sep; 60(9):1234-1239. PubMed ID: 30954943
[TBL] [Abstract][Full Text] [Related]
16. Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.
Wall JS; Foster JS; Martin EB; Kennel SJ
Pharm Pat Anal; 2017 Sep; 6(5):215-223. PubMed ID: 28825509
[TBL] [Abstract][Full Text] [Related]
17. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo.
Wall JS; Williams A; Richey T; Stuckey A; Huang Y; Wooliver C; Macy S; Heidel E; Gupta N; Lee A; Rader B; Martin EB; Kennel SJ
PLoS One; 2013; 8(6):e66181. PubMed ID: 23750281
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
